Table 1.
Cohort Characteristics
| Overall* | Indication for Primary Prevention Statin | |
|---|---|---|
| Unweighted N | 21,691 | 9,895 |
| Weighted N, billions (95% CI) | 1.96 (1.89 to 2.03) | 0.70 (0.66 to 0.73) |
| % of Overall, (95% CI) | 100 | 35.6 (34.5 to 36.8) |
|
| ||
| Demographics, % (95% CI) | ||
| Age category, y | ||
| 20–39 | 40.0 (38.9 to 41.2) | 2.2 (1.7 to 2.6) |
| 40–59 | 38.8 (37.8 to 39.8) | 43.6 (42.1 to 45.1) |
| 60–74 | 15.8 (15.0 to 16.7) | 39.4 (37.9 to 40.9) |
| ≥ 75 | 5.3 (5.0 to 5.7) | 14.9 (13.9 to 15.8) |
| Female | 51.8 (51.1 to 52.5) | 47.8 (46.4 to 49.1) |
| Race/ethnicity | ||
| Asian | 2.5 (2.1 to 2.9) | 2.3 (1.9 to 2.7) |
| Black | 12.0 (10.0 to 12.2) | 11.6 (10.2 to 13.0) |
| Hispanic | 14.2 (12.6 to 15.8) | 10.6 (9.0 to 12.1) |
| Other/Multi-Racial | 4.5 (3.9 to 5.0) | 3.7 (3.1 to 4.3) |
| White | 67.8 (65.6 to 69.9) | 71.8 (69.5 to 74.2) |
| Education | ||
| <12th Grade | 16.6 (15.6 to 17.6) | 19.9 (18.6 to 21.3) |
| High School Graduate | 23.9 (22.8 to 25.0) | 26.6 (25.0 to 28.2) |
| Some College | 31.1 (30.0 to 31.1) | 28.6 (28.0 to 30.1) |
| College Graduate | 28.3 (26.7 to 30.0) | 24.8 (23.0 to 26.6) |
| Health insurance | ||
| Commercial | 51.1 (49.8 to 52.4) | 37.9 (36.3 to 40.0) |
| Medicaid | 5.7 (5.1 to 6.2) | 5.4 (4.7 to 6.2) |
| Medicare | 17.1 (16.3 to 17.9) | 35.6 (34.2 to 37.0) |
| Other | 7.5 (6.9 to 8.1) | 9.8 (8.7 to 10.9) |
| Uninsured | 18.7 (17.6 to 19.7) | 11.3 (10.3 to 12.3) |
| Received healthcare in the past year | 81.0 (80.1 to 81.8) | 89.0 (88.1 to 90.0) |
| Usual source of healthcare | 82.6 (81.8 to 83.3) | 89.2 (88.2 to 90.0) |
| Body mass index, kg/m2 | ||
| <18.5 | 1.8 (1.5 to 2.0) | 1.0 (0.7 to 1.3) |
| 18.5–24.9 | 30.1 (29.6 to 31.7) | 22.9 (21.6 to 24.2) |
| 25–29.9 | 33.0 (32.1 to 33.9) | 35.5 (34.1 to 37.0) |
| ≥ 30 | 34.6 (33.5 to 35.7) | 40.6 (39.1 to 42.0) |
| Smoking in past year | 21.1 (20.0 to 22.2) | 22.2 (20.8 to 23.6) |
| Indication for Statin for Primary Prevention, % (95% CI) *† | ||
| Any Indication | 35.6 (34.4 to 36.8) | 100 |
| LDL≥190 mg/dL | 3.6 (3.3 to 4.0) | 10.2 (9.2 to 11.1) |
| Diabetes | 9.0 (8.5 to 9.5) | 25.3 (24.0 to 26.6) |
| ASCVD Risk ≥ 20% | 7.8 (7.3 to 8.3) | 22.0 (20.7 to 23.3) |
| ASCVD Risk 7.5% to 19.9% | 9.9 (9.3 to 10.6) | 27.9 (26.5 to 29.3) |
| ASCVD Risk 5.0% to 7.5% | 5.2 (4.8 to 5.7) | 14.7 (13.9 to 15.8) |
Note: Missing values were imputed using multiple imputation, including: smoking status (N=24), body mass index (n=344), received healthcare in the past year (N=13).
Overall cohort consists of participants meeting all eligibility criteria and without a secondary prevention indication for statin use.
Baseline ASCVD risk scores for adults taking statins were calculated using a correction factor for each statin based on prior meta-analysis data (Naci H, Brugts JJ, Fleurence R, Ades AE. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. Eur J Prev Cardiol. 2013;20(4):658–670. doi:10.1177/2047487313483600
Individual indication categories were mutually exclusive. Adults who met multiple primary prevention indications by AHA/ACC guidelines were assigned by the highest criteria met, consistent with guideline hierarchy (LDL-C criteria > diabetes status > ASCVD risk).1